Literature DB >> 8285617

Therapy of multidrug-resistant tuberculosis: lessons from studies with mice.

S P Klemens1, M S DeStefano, M H Cynamon.   

Abstract

The activities of antituberculosis agents were evaluated in a murine tuberculosis model using a drug-resistant isolate. A multidrug-resistant clinical isolate from a recent outbreak of tuberculosis in the New York State correctional system was used for infection. Approximately 10(7) viable Mycobacterium tuberculosis ATCC 49967 (strain CNL) organisms were given intravenously to 4-week-old female outbred mice. Treatment was started 1 day after infection and given for 4 weeks. Spleens and lungs were homogenized, and viable cell counts were determined. Statistical analysis indicated that ethionamide, sparfloxacin, ofloxacin, capreomycin, clarithromycin, and clofazimine are active in the murine test system with this multidrug-resistant tuberculosis isolate. Sparfloxacin is the most active quinolone. Despite in vitro resistance, isoniazid has moderate activity. In vitro susceptibility data coupled with evaluation of agents against drug-resistant isolates in the murine system should provide information necessary to design clinical trials for treatment of infections with these organisms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8285617      PMCID: PMC192390          DOI: 10.1128/AAC.37.11.2344

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Tuberculosis and human immunodeficiency virus infection.

Authors:  R E Chaisson; G Slutkin
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

2.  Multidrug-resistant tuberculosis.

Authors:  S W Dooley; W R Jarvis; W J Martone; D E Snider
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

3.  In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.

Authors:  B Ji; C Truffot-Pernot; J Grosset
Journal:  Tubercle       Date:  1991-09

Review 4.  Drug-resistant tuberculosis.

Authors:  M D Iseman; L A Madsen
Journal:  Clin Chest Med       Date:  1989-09       Impact factor: 2.878

5.  An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection.

Authors:  M A Fischl; R B Uttamchandani; G L Daikos; R B Poblete; J N Moreno; R R Reyes; A M Boota; L M Thompson; T J Cleary; S Lai
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

6.  Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers.

Authors:  M L Pearson; J A Jereb; T R Frieden; J T Crawford; B J Davis; S W Dooley; W R Jarvis
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

Review 7.  Drug treatment of tuberculosis--1992.

Authors:  P T Davidson; H Q Le
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

8.  Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.

Authors:  V Lalande; C Truffot-Pernot; A Paccaly-Moulin; J Grosset; B Ji
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

9.  Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs.

Authors:  K Brudney; J Dobkin
Journal:  Am Rev Respir Dis       Date:  1991-10

10.  In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1987-09
View more
  20 in total

Review 1.  Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.

Authors:  Kelly E Dooley; Carole D Mitnick; Mary Ann DeGroote; Ekwaro Obuku; Vera Belitsky; Carol D Hamilton; Mamodikoe Makhene; Sarita Shah; James C M Brust; Nadza Durakovic; Eric Nuermberger
Journal:  Clin Infect Dis       Date:  2012-05-21       Impact factor: 9.079

2.  Cloning, expression, purification, crystallization and X-ray crystallographic analysis of Rv2606c from Mycobacterium tuberculosis H37Rv.

Authors:  Sangwoo Kim; Kyung Jin Kim
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-04-30

3.  Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice.

Authors:  L Fattorini; Y Xiao; M Mattei; Y Li; E Iona; M L Ricci; O F Thoresen; R Creti; G Orefici
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 4.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

5.  High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.

Authors:  M H Cynamon; Y Zhang; T Harpster; S Cheng; M S DeStefano
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

6.  Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture.

Authors:  Ernestas Janulionis; Carolina Sofer; Ho-Yeon Song; Robert S Wallis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 7.  Animal and cell-culture models for the study of mycobacterial infections and treatment.

Authors:  I M Orme; A D Roberts; S K Furney; P S Skinner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

8.  Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.

Authors:  M J Hickey; T M Arain; R M Shawar; D J Humble; M H Langhorne; J N Morgenroth; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility.

Authors:  S P Klemens; C A Sharpe; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.